Our results suggest that therapeutic targeting of NLRX1 using small molecule agonists limits inflammatory neurodegeneration and could be a potential therapeutic strategy for the compartmentalized CNS inflammation that occurs in progressive MS. Here, NLRX1 is linked to myeloid sarcoma.